Compare YieldMax NVDA Option Income Strategy ETF (NVDY) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax NVDA Option Income Strategy ETF vs TransMedics Group Inc — how do they compare? YieldMax NVDA Option Income Strategy ETF trades at $12.57 (market cap $1.45B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: TransMedics Group Inc is the larger of the two by market cap, and TransMedics Group Inc is more actively traded (949,331 versus 1,943,739). Which is the better fit depends on your goals — on Pluang, investors hold YieldMax NVDA Option Income Strategy ETF for 43 Days and TransMedics Group Inc for 24 Days on average.
| NVDY | TMDX | |
|---|---|---|
Market Cap | $1.45B | $2.74B |
Volume | 1,943,739 | 949,331 |
Sector | Income / Options Overlay | Health |
52-Week High | $17.21 | $150.42 |
52-Week Low | $11.58 | $61.99 |
Typical Hold Time | 43 Days | 24 Days |
Enterprise Value | — | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVDY (YieldMax NVDA Option Income Strategy ETF) trades at $12.62, down 3.0% today amid bearish technical signals. The ETF generates income through covered calls on NVIDIA stock but faces structural limitations on upside participation. Recent analyst commentary highlights concerns about NAV erosion despite the attractive 39.7% annualized distribution rate. Technical indicators show bearish momentum with support at $12 and resistance at $13.
The outlook remains cautious as declining NVIDIA volatility reduces option income potential. While weekly distributions provide income, the capped upside and NAV erosion present significant risks for long-term investors. Analyst consensus leans toward Hold ratings, suggesting limited growth prospects despite strong underlying NVIDIA fundamentals.
TMDX trades at $79.00, down 2.55% amid bearish technical signals. The stock shows strong profitability with 22.69% net margin and 36.28% ROE, though recent earnings misses and margin compression from 2025 to 2026 raise concerns. Analyst consensus remains bullish with a $99.75 price target, but multiple legal investigations into fiduciary duties create uncertainty. Revenue growth continues with 2026 guidance at $668M.
The stock presents a growth opportunity with analyst upside potential, but faces near-term headwinds from earnings volatility and legal scrutiny. Execution on 2026 guidance and resolution of governance concerns will be critical for sustained momentum. Current valuation at 20.47 P/E appears reasonable given growth prospects if operational targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
